Back to top

Analyst Blog

Repros Therapeutics Inc. (RPRX - Snapshot Report) recently announced six months interim results from the ongoing ZA-303 study on its lead pipeline candidate, Androxal. The study is evaluating  the impact of Androxal therapy on bone mineral density in men suffering from secondary hypogonadism .

Interim data from the single-blind, placebo-controlled study suggested that the use of Androxal did not result in bone loss as compared to placebo. Additionally, data hinted that Androxal may improve bone mineral density.

Top-line twelve-month data from the study are expected in the second quarter of 2014. The company plans to file a New Drug Application to the U.S. Food and Drug Administration (FDA) for Androxal by mid 2014.

The company is also evaluating Androxal in other studies for secondary hypogonadism including two pivotal phase III studies conducted under the FDA’s Special Protocol Assessment program.

Earlier this year, the company had announced encouraging top-line data from the first pivotal phase III study (ZA-301). The second pivotal phase III study is expected to be completed in the fourth quarter of 2013.

Currently prescribed therapies for secondary hypogonadism include AbbVie Inc.’s (ABBV - Analyst Report) AndroGel.

Apart from Androxal, Proellex is another interesting pipeline candidate at Repros. Proellex is being developed for uterine fibroids (phase IIb study expected to be initiated in the fourth quarter 2013) and endometriosis (phase II study expected to be completed in the second quarter 2014).

Repros currently carries a Zacks Rank #4 (Sell). We expect investor focus to remain on Androxal updates.

Currently, companies like Actelion Ltd. (ALIOF) and Biogen Idec Inc. (BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%